Compare IMUX & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | ONL |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 165.4M |
| IPO Year | 2013 | 2021 |
| Metric | IMUX | ONL |
|---|---|---|
| Price | $7.20 | $2.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $43.09 | N/A |
| AVG Volume (30 Days) | ★ 392.8K | 318.0K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $147,647,000.00 |
| Revenue This Year | N/A | $1.67 |
| Revenue Next Year | N/A | $0.11 |
| P/E Ratio | ★ N/A | $11.32 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $1.89 |
| 52 Week High | $17.43 | $3.05 |
| Indicator | IMUX | ONL |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 38.23 |
| Support Level | $6.35 | $2.02 |
| Resistance Level | $8.60 | $2.59 |
| Average True Range (ATR) | 0.65 | 0.08 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 36.89 | 41.49 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.